LUMO - Lumos Pharma, Inc. Stock Price and Quote

Index	-	P/E	-	EPS (ttm)	-3.68	Insider Own	9.70%	Shs Outstand	8.24M	Perf Week	8.20%
Market Cap	30.09M	Forward P/E	-	EPS next Y	-3.26	Insider Trans	-0.34%	Shs Float	5.57M	Perf Month	23.46%
Income	-30.70M	PEG	-	EPS next Q	-1.09	Inst Own	30.80%	Short Float / Ratio	3.03% / 13.08	Perf Quarter	14.80%
Sales	2.10M	P/S	14.33	EPS this Y	-1.60%	Inst Trans	7.89%	Short Interest	0.17M	Perf Half Y	-25.73%
Book/sh	6.37	P/B	0.59	EPS next Y	18.10%	ROA	-40.80%	Target Price	18.33	Perf Year	-50.84%
Cash/sh	7.25	P/C	0.52	EPS next 5Y	15.20%	ROE	-48.30%	52W Range	2.95 - 9.56	Perf YTD	4.31%
Dividend	-	P/FCF	-	EPS past 5Y	29.10%	ROI	-53.70%	52W High	-60.61%	Beta	0.93
Dividend %	-	Quick Ratio	12.60	Sales past 5Y	-44.40%	Gross Margin	-	52W Low	27.64%	ATR	0.27
Employees	33	Current Ratio	12.60	Sales Q/Q	600.00%	Oper. Margin	-	RSI (14)	61.32	Volatility	8.37% 7.97%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	3.50%	Profit Margin	-	Rel Volume	1.58	Prev Close	3.68
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 03 AMC	Payout	-	Avg Volume	12.88K	Price	3.77
Recom	2.00	SMA20	10.19%	SMA50	12.68%	SMA200	-30.31%	Volume	20,388	Change	2.18%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-21	Upgrade	Stifel	Hold → Buy	$4 → $24
Dec-03-20	Initiated	Cantor Fitzgerald	Buy	$32
Aug-26-20	Initiated	Piper Sandler	Overweight	$26
Aug-17-20	Resumed	ROTH Capital	Buy	$51
Aug-04-20	Initiated	H.C. Wainwright	Buy	$33

May-25-23 08:00AM	Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st (GlobeNewswire)
May-22-23 09:00AM	Lumos Pharma to Participate in World Orphan Drug Congress USA (GlobeNewswire) +6.61%
May-08-23 08:00AM	Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES) (GlobeNewswire)
May-03-23 04:05PM	Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates (GlobeNewswire)
Apr-27-23 09:00AM	Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES) (GlobeNewswire)
09:00AM	Loading…
Apr-19-23 09:00AM	Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023 (GlobeNewswire) -5.83%
Mar-09-23 04:05PM	Lumos Pharma to Participate in Oppenheimers 33rd Annual Healthcare Conference Held Virtually March 13-15, 2023 (GlobeNewswire)
Mar-05-23 02:00PM	Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology (GlobeNewswire)
Mar-01-23 04:05PM	Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates (GlobeNewswire)
Feb-28-23 04:05PM	Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD (GlobeNewswire) +5.20%
Feb-15-23 04:05PM	Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023 (GlobeNewswire)
Jan-03-23 09:00AM	Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023 (GlobeNewswire) +8.03%
Dec-12-22 07:30AM	KOL Review of Lumos Pharmas Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients (GlobeNewswire) -15.75%
Nov-29-22 04:05PM	Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD (GlobeNewswire)
Nov-22-22 04:05PM	Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire) +5.85%
06:10AM	Loading…
Nov-14-22 06:10AM	Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates (GlobeNewswire) -34.68%
06:00AM	Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency (GlobeNewswire)
Sep-26-22 04:05PM	Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference (GlobeNewswire)
Aug-31-22 09:00AM	Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-16-22 07:30AM	Lumos Pharma Announces Share Repurchase Program (GlobeNewswire)
Aug-09-22 04:01PM	Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates (GlobeNewswire) -5.26%
Jul-27-22 04:05PM	Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022 (GlobeNewswire)
Jul-24-22 08:27AM	Quite a few insiders invested in Lumos Pharma, Inc. (NASDAQ:LUMO) last year which is positive news for shareholders (Simply Wall St.)
Jul-20-22 08:32PM	Our long-term outlook for the stock market remains bullish: Here are 2 stocks that Oppenheimer likes (TipRanks)
May-16-22 04:05PM	Lumos Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-10-22 04:01PM	Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates (GlobeNewswire)
May-06-22 10:25AM	Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation (Simply Wall St.)
May-05-22 09:00AM	Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial (GlobeNewswire)
Apr-26-22 09:00AM	Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022 (GlobeNewswire) +7.50%
Apr-11-22 08:30AM	Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD (GlobeNewswire)
04:05PM	Loading…
Mar-23-22 04:05PM	Lumos Pharma to Participate in the Cantor Rare Disease Symposium (GlobeNewswire)
Mar-10-22 04:01PM	Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials (GlobeNewswire)
09:00AM	Lumos Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-23-22 09:00AM	Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022 (GlobeNewswire)
Feb-14-22 12:05PM	Great news for Lumos Pharma, Inc. (NASDAQ:LUMO): Insiders acquired stock in large numbers last year (Simply Wall St.)
Jan-05-22 09:00AM	Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference (GlobeNewswire)
Dec-28-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-21-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com) +6.19%
Dec-16-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-08-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com) +6.03%
Nov-24-21 10:00AM	Down 16.1% in 4 Weeks, Here's Why Lumos (LUMO) Looks Ripe for a Turnaround (Zacks)
Nov-15-21 11:14AM	We're Hopeful That Lumos Pharma (NASDAQ:LUMO) Will Use Its Cash Wisely (Simply Wall St.)
Nov-10-21 05:06PM	Lumos Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-08-21 10:42AM	Wall Street Analysts Predict a 190% Upside in Lumos (LUMO): Here's What You Should Know (Zacks)
Nov-03-21 04:01PM	Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates (GlobeNewswire)
Oct-21-21 04:05PM	Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021 (GlobeNewswire)
Sep-02-21 08:00AM	Lumos Pharma to Participate in September Investor Conferences (GlobeNewswire)
Aug-16-21 09:58AM	Great news for Lumos Pharma, Inc. (NASDAQ:LUMO): Insiders acquired stock in large numbers last year (Simply Wall St.)
Aug-05-21 08:00AM	Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates (GlobeNewswire)
Aug-03-21 08:00AM	Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer (GlobeNewswire) -9.04%
Aug-02-21 08:00AM	Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President (GlobeNewswire) +10.66%
Jul-26-21 04:18PM	Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board (GlobeNewswire)
Jul-22-21 08:00AM	Lumos Pharma to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021 (GlobeNewswire)
Jul-20-21 04:01PM	Lumos Pharma Announces Clinical Updates (GlobeNewswire)
Jun-28-21 08:00AM	Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment (GlobeNewswire)
May-19-21 09:00AM	Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-13-21 09:00AM	Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit (GlobeNewswire)
May-05-21 04:01PM	Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates (GlobeNewswire) -7.41%
02:30PM	Lumos Pharma Inc to Host Earnings Call (ACCESSWIRE)
Apr-28-21 09:00AM	Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021 (GlobeNewswire)
Apr-27-21 08:00AM	Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar (GlobeNewswire)
Apr-20-21 04:05PM	Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession (GlobeNewswire)
Apr-14-21 04:05PM	Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency (GlobeNewswire) +5.78%
Mar-20-21 11:00AM	Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency (GlobeNewswire)
Mar-11-21 04:05PM	Lumos Pharma to Participate in March 2021 Investor Conferences (GlobeNewswire)
Mar-09-21 04:05PM	Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD (GlobeNewswire)
01:30PM	Lumos Pharma Inc to Host Earnings Call (ACCESSWIRE)
Mar-04-21 09:00AM	Data Supporting Use of Predictive Enrichment Markers for Lumos Pharmas LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society (GlobeNewswire) -5.82%
Mar-02-21 04:05PM	Lumos Pharma to Present Poster Demonstrating Greater GH Response to LUM-201 than to Standard GH Secretagogues in PGHD at the Endocrine Society (ENDO) 2021 Annual Meeting (GlobeNewswire)
12:30PM	Will Lumos Pharma (LUMO) Report Negative Earnings Next Week? What You Should Know (Zacks)
Feb-22-21 04:15PM	Lumos Pharma to Report Full Year 2020 Financial Results and Host Conference Call on March 9, 2021 (GlobeNewswire) -5.92%
Feb-16-21 04:01PM	Lumos Pharma Announces Changes to its Board of Directors (GlobeNewswire)
Dec-18-20 09:00AM	Lumos Pharma to Participate in the H.C. Wainwright BioConnect 2021 Conference (GlobeNewswire)
Dec-16-20 02:19AM	What You Need To Know About Lumos Pharma, Inc.'s (NASDAQ:LUMO) Investor Composition (Simply Wall St.) +15.38%
Nov-30-20 05:35PM	Is Lumos Pharma (LUMO) A Good Stock To Buy Now? (Insider Monkey)
Nov-23-20 07:43PM	Lumos Pharma to Participate in December Investor Conferences (GlobeNewswire)
Nov-10-20 04:01PM	Lumos Pharma Announces the Initiation of Phase 2b OraGrowtH210 Trial and Reports Third Quarter 2020 Financial Results (GlobeNewswire)
02:30PM	Lumos Pharma Inc to Host Earnings Call (ACCESSWIRE)
Nov-03-20 12:30PM	Lumos Pharma (LUMO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-29-20 09:00AM	Lumos Pharma to Participate in November Investor Conferences (GlobeNewswire)
Oct-27-20 04:01PM	Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020 (GlobeNewswire)
Aug-27-20 09:00AM	Lumos Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-20 04:01PM	Lumos Pharma Reports Second Quarter 2020 Results and Provides Update on Clinical and Corporate Activities (GlobeNewswire)
Jul-28-20 04:01PM	Lumos Pharma to Report Second Quarter 2020 Financial Results and Host a Conference Call on August 13, 2020 (GlobeNewswire)
Jul-27-20 04:05PM	Lumos Pharma Announces Sale of Priority Review Voucher (GlobeNewswire)
Jun-19-20 08:21AM	Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jun-10-20 03:41PM	Is Lumos Pharma, Inc. (LUMO) A Good Stock To Buy? (Insider Monkey)
May-28-20 04:01PM	Lumos Pharma Reports First Quarter 2020 Results and Provides Update on Clinical and Corporate Activities (GlobeNewswire)
May-27-20 04:27PM	Lumos Pharma to Participate in the Jefferies 2020 Healthcare Conference (GlobeNewswire)
May-26-20 10:36AM	Lumos Pharma to Report First Quarter 2020 Financial Results and Host a Conference Call on May 28, 2020 (GlobeNewswire)
Apr-24-20 08:00AM	Lumos Pharma Hires Biotech Veteran Aaron Schuchart as Chief Business Officer (GlobeNewswire)
Apr-02-20 04:05PM	Lumos Pharma Promotes John C. McKew, PhD to Chief Operating Officer and Chief Scientific Officer (GlobeNewswire)

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McKew John C.	Chief Scientific Officer	Apr 04	Sale	3.27	2,214	7,240	23,207	Apr 04 05:22 PM
McKew John C.	Chief Scientific Officer	Feb 02	Sale	3.53	439	1,550	26,457	Feb 03 05:03 PM
McCracken Joseph S	Director	Nov 16	Buy	5.03	4,000	20,120	15,721	Nov 18 04:31 PM
Hawkins Richard J	Chief Executive Officer	Sep 23	Buy	8.80	208	1,830	4,469	Sep 23 05:05 PM
Hawkins Richard J	Chief Executive Officer	Sep 21	Buy	8.84	2,214	19,572	4,261	Sep 23 05:05 PM
Hawkins Richard J	Chief Executive Officer	Sep 20	Buy	8.75	1,506	13,178	2,047	Sep 21 06:45 PM
Hawkins Richard J	Chief Executive Officer	Sep 19	Buy	8.65	541	4,680	541	Sep 21 06:45 PM
McCracken Joseph S	Director	Aug 25	Buy	8.60	3,170	27,262	11,721	Aug 26 04:59 PM
Raffin Thomas A.	Director	Aug 25	Buy	8.46	1,150	9,729	9,406	Aug 26 05:00 PM
McKew John C.	Chief Scientific Officer	Aug 02	Sale	8.11	3,407	27,631	24,602	Aug 03 11:25 AM
McKew John C.	Chief Scientific Officer	Jun 06	Sale	7.62	169	1,288	29,102	Jun 07 04:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience